Prior to joining OPKO, Dr. Strugnell founded Strugnell Consulting LLC in early 2010 and provided consulting services to the pharmaceutical industry and research foundations. Previously, Dr. Strugnell had served as Associate Scientific Director of Genzyme (NASDAQ: GENZ), a leading biotechnology company, from July 2005 to December 2009, working in multiple areas including Research & Development, Regulatory Affairs, and Product Support. During the period of January 1998 to June 2005, Dr. Strugnell served as Associate Director, Preclinical Research at Bone Care International, Inc. (NASDAQ: BCII), a public specialty pharmaceutical company focused on developing and commercializing vitamin D hormone therapies. Prior to joining Bone Care, Dr. Strugnell completed a four-year post-doctoral fellowship with Dr. Hector DeLuca, a world leader in vitamin D research and discoverer of many vitamin D compounds and analogs, and received his PhD degree in Biochemistry from Queen’s University under the direction of Dr. Glenville Jones, a world leader in the study of vitamin D metabolism.